Analyst Ratings February 23, 2026

Mizuho Begins Coverage of Tango Therapeutics, Rates Stock Outperform with $19 Target

Analyst highlights vopimetostat's potential in MTAP-deleted tumors and sees 2026 clinical updates as key catalysts

By Avery Klein TNGX
Mizuho Begins Coverage of Tango Therapeutics, Rates Stock Outperform with $19 Target
TNGX

Mizuho has started coverage of Tango Therapeutics Inc. (NASDAQ:TNGX) with an outperform rating and a $19.00 price target, signaling expected upside from the current trading level of $12.20. The research note underscores the commercial and clinical promise of vopimetostat, an MTA-cooperative PRMT5 inhibitor the firm views as a first-in-class and potential best-in-class therapy both as a single agent and in combination with RAS(ON) inhibitors for MTAP-deleted pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Mizuho expects clinical data in 2026 to clarify the monotherapy profile and demonstrate additive benefit when combined with RAS(ON) inhibitors, and projects $1.8 billion in risk-adjusted vopimetostat sales worldwide by 2035.

Key Points

  • Mizuho initiated coverage of Tango Therapeutics with an outperform rating and a $19.00 price target; the stock was trading at $12.20 at the time of the note.
  • Vopimetostat, an MTA-cooperative PRMT5 inhibitor, is cited as the primary value driver, with potential as a first-in-class and best-in-class agent as monotherapy and in combination with RAS(ON) inhibitors for MTAP-deleted PDAC and NSCLC.
  • Mizuho projects $1.8 billion in risk-adjusted global vopimetostat sales by 2035 and identifies 2026 Phase I readouts as a key catalyst for potential stock outperformance.

Mizuho has formally initiated coverage of Tango Therapeutics Inc. (NASDAQ:TNGX), assigning the stock an outperform rating and establishing a $19.00 price target. At the time of the note the company’s shares were trading at $12.20, which Mizuho says implies meaningful upside to its valuation.

Data from InvestingPro cited by the research indicates the stock has returned 417% over the past 12 months, although the platform’s Fair Value analysis flags the shares as potentially overvalued at current levels.


Central to Mizuho’s thesis is vopimetostat, described in the note as an MTA-cooperative PRMT5 inhibitor with the potential to be both a first-in-class and best-in-class asset. The firm highlights the drug’s development as a monotherapy and in combination with RAS(ON) inhibitors, targeting MTAP-deleted tumors in PDAC and NSCLC.

Mizuho expects further clinical updates in 2026 that should clarify vopimetostat’s monotherapy efficacy and provide early signals as to whether the RAS(ON) inhibitor combinations deliver additive benefit. The research team states the incremental efficacy required for vopimetostat to show clinically meaningful additive responses relative to RAS(ON) monotherapy is readily achievable, with particular emphasis on second-line and later PDAC settings.

Looking to positioning, Mizuho anticipates the combinations could be advanced as novel frontline strategies should the clinical program support such use. Based on its model, the firm projects $1.8 billion in risk-adjusted worldwide sales for vopimetostat by 2035.


From a stock performance perspective, Mizuho expects positive Phase I readouts in 2026 to act as a material catalyst that could drive significant outperformance versus the broader market and peer group, contingent on the data aligning with the firm’s efficacy expectations.

The research note also references available proprietary analysis on the program through a comprehensive Pro Research Report on InvestingPro, which the firm says converts complex datasets into actionable research for investors.


Other recent analyst and corporate developments were noted alongside Mizuho’s initiation. Stifel has reaffirmed a Buy rating and a $15.00 price target after updates related to Tango’s strategic priorities and the dosing of patients in the vopimetostat plus RAS(ON) inhibitor combination study. The firm’s stance reflects continued confidence in the pipeline, including vopimetostat’s positioning as a potential best-in-class PRMT5 inhibitor.

On the corporate governance front, Tango announced a leadership transition. Malte Peters will assume the role of President and Chief Executive Officer, while founding CEO Barbara Weber will move to Executive Chair for 2026. The company also appointed Sung Lee to its board of directors; Lee is cited as bringing more than two decades of finance leadership and currently serves as Executive Vice President and Chief Financial Officer at Cytokinetics.

These recent analyst assessments and management changes underscore an active period for the company as it advances its lead program and retools its leadership structure ahead of anticipated clinical milestones in 2026.

Risks

  • Valuation risk - InvestingPro’s Fair Value analysis suggests the stock may be overvalued at current levels, indicating market expectations may already price in substantial upside.
  • Clinical and timing uncertainty - Mizuho’s thesis relies on clinical updates in 2026 to validate monotherapy activity and additive benefit in RAS(ON) combinations, and those data remain pending.
  • Program and positioning risk - The commercial case assumes combinations can be positioned as novel frontline strategies; achieving that positioning depends on future clinical results and regulatory or market acceptance.

More from Analyst Ratings

Aletheia Capital Raises Nvidia to Buy, Cites Strong AI Demand and Channel Normalization Feb 23, 2026 Citizens Keeps Outperform Rating on DraftKings; Sees Significant Upside Despite Soft Guidance Feb 23, 2026 Citizens Upholds Outperform Call on Savara Ahead of MOLBREEVI FDA Decision Feb 23, 2026 Citizens Keeps Market Perform on Western Union as Digital Shift and Macro Pressure Persist Feb 23, 2026 Citizens Sticks with Market Outperform on Bicara Therapeutics, Cites Durable Clinical Data and Strong Cash Position Feb 23, 2026